Veren Inc

VRN

Equity

ISIN null / Valor 135002270

Toronto Stock Exchange (2025-05-13)

CAD 9.14+3.86%

Veren Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Veren Inc. specializes in developing and commercializing innovative medical devices aimed at improving the treatment of chronic sinusitis.

Summarized from source with an LLMView SourceSector: Energy

Excess Cash Flow Generation

In Q4 2024, Veren Inc. generated excess cash flow of $203.8 million, contributing to a full-year excess cash flow of $641.6 million. This robust cash flow was driven by focused development and a high-quality asset base.

Return to Shareholders

During the fourth quarter, Veren returned $105.7 million to shareholders through dividends and share repurchases. For the full year 2024, the company returned $385.7 million, representing 60 percent of excess cash flow, underscoring its commitment to shareholder returns.

Net Debt Reduction

Veren Inc. successfully reduced its net debt by $481.5 million in Q4 2024, achieving a 35 percent reduction for the full year. This was accomplished through excess cash flow generation and proceeds from strategic asset dispositions.

Production Growth

In the fourth quarter, Veren achieved an average production of 188,721 boe/d, with significant contributions from its Alberta Montney and Kaybob Duvernay assets. For the full year, average production reached 191,163 boe/d, aligning with company guidance.

Outlook for 2025

Veren Inc. expects to generate excess cash flow of $625 million to $825 million in 2025, based on WTI prices ranging from US$70/bbl to US$75/bbl. The company continues to focus on maximizing asset potential and maintaining a strong financial position.

Summarized from source with an LLMView Source

Key figures

-22.3%1Y

%3Y

%5Y

Performance

53.2%1Y

41.5%3Y

41.5%5Y

Volatility